Literature DB >> 9949631

Increased bcl-2/bax ratio in B-cell chronic lymphocytic leukemia is associated with a progressive pattern of disease.

S Molica, A Dattilo, C Giulino, D Levato, L Levato.   

Abstract

In order to evaluate clinical implications of altered expression of bcl-2 and bax proteins in B-cell chronic lymphocytic leukemia (CLL) we studied 27 patients with this disease. Cytofluorometric levels of bcl-2 did not reflect the status of disease. In contrast bax expression was lower in progressive than in non-progressive disease, therefore leading to a higher bcl-2/bax ratio in patients of the former group. If confirmed in longitudinal studies, quantitative cytofluorometric evaluation of bcl-2 and bax protein might help to identify patients with progressive disease who could possibly benefit from early therapy.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9949631

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  9 in total

Review 1.  Bcl-2 and apoptosis in chronic lymphocytic leukemia.

Authors:  Aaron D Schimmer; Irene Munk-Pedersen; Mark D Minden; John C Reed
Journal:  Curr Treat Options Oncol       Date:  2003-06

Review 2.  Know the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemia.

Authors:  Ying Huang; Jia-Zhu Wu; Jian-Yong Li; Wei Xu
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

3.  Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia.

Authors:  Maria Ilaria Del Principe; Michele Dal Bo; Tamara Bittolo; Francesco Buccisano; Francesca Maria Rossi; Antonella Zucchetto; Davide Rossi; Riccardo Bomben; Luca Maurillo; Mariagiovanna Cefalo; Giovanna De Santis; Adriano Venditti; Gianluca Gaidano; Sergio Amadori; Paolo de Fabritiis; Valter Gattei; Giovanni Del Poeta
Journal:  Haematologica       Date:  2015-11-12       Impact factor: 9.941

4.  Quercetin downregulates Mcl-1 by acting on mRNA stability and protein degradation.

Authors:  C Spagnuolo; C Cerella; M Russo; S Chateauvieux; M Diederich; G L Russo
Journal:  Br J Cancer       Date:  2011-07-12       Impact factor: 7.640

5.  The Role of BCL2 Family of Apoptosis Regulator Proteins in Acute and Chronic Leukemias.

Authors:  Flora Tzifi; Christina Economopoulou; Dimitrios Gourgiotis; Alexandros Ardavanis; Sotirios Papageorgiou; Andreas Scorilas
Journal:  Adv Hematol       Date:  2011-09-14

6.  Gene expression of INPP5F as an independent prognostic marker in fludarabine-based therapy of chronic lymphocytic leukemia.

Authors:  G Palermo; D Maisel; M Barrett; H Smith; G Duchateau-Nguyen; T Nguyen; R-F Yeh; A Dufour; T Robak; D Dornan; M Weisser
Journal:  Blood Cancer J       Date:  2015-10-02       Impact factor: 11.037

7.  Association of Bax Expression and Bcl2/Bax Ratio with Clinical and Molecular Prognostic Markers in Chronic Lymphocytic Leukemia.

Authors:  Ksenija Vucicevic; Vladimir Jakovljevic; Natasa Colovic; Natasa Tosic; Tatjana Kostic; Irena Glumac; Sonja Pavlovic; Teodora Karan-Djurasevic; Milica Colovic
Journal:  J Med Biochem       Date:  2016-05-09       Impact factor: 3.402

8.  Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells.

Authors:  Carmela Ciardullo; Erhan Aptullahoglu; Laura Woodhouse; Wei-Yu Lin; Jonathan P Wallis; Helen Marr; Scott Marshall; Nick Bown; Elaine Willmore; John Lunec
Journal:  Haematologica       Date:  2019-04-19       Impact factor: 9.941

9.  ZGDHu-1 for cancer therapy.

Authors:  Jinlin Liu; Liannv Qiu; Jun Xia; Sufeng Chen; Xiping Yu; Yonglie Zhou
Journal:  Oncol Lett       Date:  2017-09-28       Impact factor: 2.967
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.